Lupin Manufacturing Solutions (LMS), a subsidiary of Lupin Limited, has commissioned a dedicated Oncology Block at its Vizag facility in India. This new high-containment unit enhances LMS’s capabilities for High Potent Active Pharmaceutical Ingredients (APIs), supporting oncology development from preclinical research to commercial manufacturing. The facility spans 4,270 square meters and features advanced containment systems, ensuring safe production of oncology APIs.
New Oncology Manufacturing Capabilities
Lupin Manufacturing Solutions (LMS) has announced the launch of its dedicated Oncology Block at the Vizag facility. This expansion significantly enhances the company’s ability to manufacture High Potent APIs for oncology drugs, supporting clients from the early stages of drug development through to full-scale commercial production. The new block was announced on November 12, 2025.
Facility Details and Features
The new facility spans 4,270 square meters and is equipped with 20 reactors ranging from 250L to 2000L. It incorporates over 20 isolators and advanced containment systems, ensuring an exposure level of ≤0.05 µg/m³. Designed for flexible scale-up capabilities (1–35 kg batch range) and comprehensive environmental controls (≤25°C, ≤45% RH), the facility ensures safe and efficient production that meets global quality standards.
Integrated Process and Quality Control
The facility integrates a Process Development Laboratory with a dedicated Quality Control laboratory, facilitating early-stage route scouting, analytical development, and process optimization all in one location. Supported by specialized scientists, this setup ensures a seamless transition from lab-scale synthesis to commercial manufacturing.
Commitment to Safety and Compliance
The facility features advanced containment infrastructure and isolator-based operations. It also incorporates integrated SCADA systems and a robust effluent detoxification system. These features are designed to ensure compliance with global regulatory standards while adhering to Lupin’s stringent safety and environmental protocols.
Strategic Expansion for Oncology Innovation
With this expansion, LMS strengthens its position as a trusted global CDMO partner for oncology innovators, offering faster, safer, and more efficient development of oncology treatments. This integration leverages Lupin’s scientific legacy with advanced containment facilities.
Source: BSE
